Tid
1.9.2021–31.8.2023
Projektägare
Åbo Akademi
Finansiär
Budget
250 000 euro
Åbo Akademis del av budgeten
250 000 euro (100%)
One of the major scopes of the project is to shed light on the “dark matter of the biological universe”, the glycans, recognized by Sialic acid-binding immunoglobulin (Ig)-like lectin 9 (Siglec-9) in inflammation and cancer. Siglec-9 regulates the innate and adaptive immune systems by recognizing sialic acids on the surface sialoglycans of its binding partners. These interactions have a role in many infectious diseases, inflammation, neurodegeneration, autoimmune diseases, and cancer, which makes the sialic acid–Siglec axis an emerging target to prevent or affect these diseases.
The project aims to unveil the multivalent Siglec-9 interactions and design novel inhibitors that block all Siglec-9-mediated interactions in inflammation and cancer. The designed inhibitors will serve as a starting point for the development of anti-inflammatory and anti-cancer agents.
Kontakta oss
Tiina Salminen
Professor
i biokemi
Cellbiologi
Tfn +358 405151201